The link between CBD, the risk of saliva tests, and new European limits is raising increasing questions among consumers. Between roadside checks, differing regulations across countries, and regulatory changes expected in 2026, it is becoming essential to distinguish between CBD itself, residual THC , and the legal framework applicable to hemp- derived products in France and the European Union
For adults seeking lab-tested and compliant CBD products, the issue is twofold: on the one hand, food safety, with its novel food status and the reservations of the EFSA (European Food Safety Authority); on the other, road safety, because a product that is legal for sale does not automatically offer protection against a positive THC saliva test. Here's what you need to understand, without being alarmist, but also without being naive.
CBD and saliva tests: what the tests actually detect
The most important point to remember is simple: a roadside saliva test does not look for CBD, but for THC. In practice, cannabidiol is not the substance targeted by drug tests while driving. The risk of a positive result therefore comes from the presence of traces of THC in some CBD products, even when they are marketed as legal.
Official French information states that a CBD product containing no trace of THC should not lead to a positive result. However, it also specifies that products actually sold on the market may contain small amounts of THC. This is where the real risk for drivers lies: not in the word "CBD" on the label, but in the actual composition of the product consumed.
In other words, consumers may think they are in a safe position because they are not buying cannabis high in THC, when in fact the legal risk comes from a legal but detectable residual amount. This distinction is crucial for anyone using flowers, resins, oils, or other hemp derivatives before driving.
Why a legal CBD product can still produce positive results
In France, the official Drugs Info Service fact sheet indicates that consuming CBD containing 0.3% THC or less can still result in a positive saliva test up to 3 hours after ingestion. This is very concrete information, as it shows that a product can comply with commercial regulations while creating an immediate risk during a roadside check.
The MILDECA also reminds us that a driver can test positive for THC after consuming CBD products, even though these products are legal for sale. This confirms a frequently misunderstood reality: the legality of the product does not negate the need for drug testing. Road traffic law focuses on the presence of THC in the body, not on whether you have regularly purchased an item in a store or online.
The well-known 0.3% THC threshold in cannabis should therefore never be interpreted as immunity from driving. This threshold applies to the agricultural and commercial context of certain products, but it does not protect against a saliva test. For the driver, the real question is not "Is the product legal?", but "Is there still detectable THC in my saliva or blood?"
France remains at zero tolerance for THC while driving
The French framework is particularly strict. The decree governing drug testing stipulates saliva or blood samples to detect the presence of narcotics, with a zero-tolerance approach to THC while driving. In this context, there is no safe level of THC that a CBD user could rely on to drive with peace of mind after use.
In practical terms, if traces of THC are detected, the defense of saying “I only consumed CBD” doesn't offer the security one might expect. The official guidelines for 2026 are, on the contrary, very clear: “CBD only” use can still lead to the detection of THC in saliva or blood if the product contained residual traces.
For this reason, maximum caution remains the only true strategy. Even for informed, well-intentioned adult consumers, legal risk exists. When it comes to driving, one must think in terms of zero risk, especially with products recently inhaled or consumed.
The rules vary greatly depending on the European country
At the European level, there is no single limit regarding THC while driving. EUDA points out that member states apply widely varying approaches: some use impairment-based criteria, others set numerical thresholds, and still others implement very strict regimes approaching zero tolerance. As a result, behavior perceived as acceptable in one country can lead to immediate legal repercussions in another.
THC saliva tests are now widely used in Europe. According to EUDA, over the past ten years, oral screening devices have been used in 15 European countries, including France. The procedure often includes an initial saliva test, sometimes supplemented by a behavioral assessment, followed by a confirmatory blood test.
For consumers who travel, this heterogeneity changes everything. A CBD product legally purchased in one EU country does not guarantee the same tolerance, the same interpretation by law enforcement, or the same administrative consequences elsewhere. Before crossing borders, it is therefore essential to check not only the legality of the product, but also the local policy regarding THC detection while driving.
New European limits: CBD remains a novel food under surveillance
In the food sector, the European Union continues to classify CBD as a novel food when it falls within the scope of applicable EU legislation. This means that there is still no general and automatic marketing authorization for all CBD food products. In 2026, the European Commission published several terminating procedure concerning various applications related to cannabidiol, CBD isolate, CBD oil, and CBD tincture.
These completed procedures did not result in inclusion on the EU list of authorized novel foods. In short, the framework remains incomplete, evolving, and cautious. For both professionals and consumers, this means closely monitoring official publications from the European Commission, particularly the page dedicated to novel foods and the list of authorizations or terminations of procedures.
This regulatory situation sometimes leads to confusion: many people believe that because CBD is visible on the market, its status as a food product is now fully established. This is not the case. In 2026, Europe maintained a level of vigilance, both for reasons of health safety and the quality of the submitted scientific dossiers.
What EFSA says in 2026 about the safety of CBD
On February 9, 2026, the EFSA set a provisional safe dose for CBD in adults at 0.0275 mg/kg/day, or approximately 2 mg per day for a 70 kg person. This figure has attracted considerable attention, as it finally provides a quantifiable benchmark. However, it should not be interpreted as a broad and definitive green light: the European agency maintains significant reservations regarding long-term safety.
The EFSA (European Food Safety Authority) reiterates that the safety of CBD cannot be established for those under 25, pregnant or breastfeeding women , or individuals undergoing medical treatment. It also points out significant data gaps regarding the liver, as well as the endocrine, nervous, and reproductive systems. In other words, the European regulatory approach is based on ongoing scientific questions, not simply on administrative posturing.
For consumers, this implies a more mature approach to CBD. A well-sourced, lab-tested, and compliant product remains preferable to a vague or opportunistic offering. But even with a good product, it's important to keep in mind that the regulatory landscape of 2026 doesn't yet consider the issue definitively settled, especially regarding repeated or edible use.
France will further tighten regulations on CBD food products in 2026
In France, the regulations regarding CBD for food useDrogues Info Service reports that, as of May 15, 2026, CBD food products such as oils, herbal teas, candies, cakes, and syrups are prohibited under the European regulation on novel foods.
This point is crucial because it shows that the debate surrounding CBD isn't limited to driving. There are two distinct issues at play: on the one hand, food safety and market compliance; on the other, road safety and the risk of THC detection. A product can therefore pose a regulatory problem for food, a problem for driving, or both, depending on its nature and use.
For buyers, this reinforces the importance of choosing transparent companies that can document the composition, analyses, and regulatory status of their products. In a rapidly evolving market, clarity regarding laboratories, cannabinoids present, and legal compliance is no longer a bonus; it's a fundamental selection criterion.
How to practically reduce the risk when consuming CBD
The first rule is simple: do not drive after consuming a CBD product that may contain residual THC, even if it is legal and even if the desired effect is not psychoactive. Official French data shows that a positive saliva test can occur after consuming products with low THC content. If you must drive, abstaining remains the safest option.
The second rule is to prioritize products that have been laboratory tested, with accessible analyses, clear traceability, and honest communication about the potential presence of THC. This doesn't automatically make the product a "safe for driving" solution, but it at least helps avoid opaque offers, misleading labeling, and poorly controlled concentrations.
Finally, it's essential to stay informed about regulatory developments. The European market for -derived products is evolving rapidly, as highlighted by EUDA, and authorities are gradually clarifying their control frameworks. Between saliva tests, national positions on THC and driving, and European decisions on novel foods, reliable information is your best ally for responsible consumption.
In summary, the issue of CBD, the risk of saliva tests, and new European limits hinges on a key distinction: CBD is not the target of roadside drug tests, but residual THC can be enough to cause a problem, even with a legal product. In France, the zero-tolerance policy for driving requires extreme vigilance, and at the European level, the lack of complete harmonization further complicates matters for consumers.
At the same time, the regulatory framework for CBD remains cautious. The EFSA set a very low provisional dose in 2026 while maintaining numerous reservations, and the European Commission continues to treat CBD as a novel food without general market authorization. The best approach today is therefore to prioritize quality, analytical transparency, and responsible consumption, with one golden rule remaining unchanged: no driving after using a CBD product that may contain THC.
